Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52193
Conference/Presentation Title: Comparative analysis of pulmonary vein isolation (PVI) alone versus PCI with additional left atrial posterior wall isolation by pulsed field ablation: a single-centre study.
Authors: Saleemi S.;Dashwood A.;Kader Z.;Bi A.;Ky V.;Young J.;Tian B.;Maung A.;Alison J. ;Kotschet E. ;Healy S.;Alasti M.;Han H.;Bittinger L.;Machado C.;Adam D. 
Monash Health Department(s): Cardiology (MonashHeart)
Institution: (Saleemi, Dashwood, Kader, Bi, Ky, Young, Alison, Kotschet, Healy, Alasti, Han, Bittinger, Machado, Adam) Monash Health, Melbourne, VIC, Australia
(Tian, Maung) Monash University, Melbourne, VIC, Australia
Presentation/Conference Date: 30-Jul-2024
Copyright year: 2024
Publisher: Elsevier Ltd
Publication information: Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. Perth Convention and Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S425), 2024. Date of Publication: August 2024.
Journal: Heart Lung and Circulation
Abstract: Background: Left atrial posterior wall isolation (LAPWI) presents challenges, particularly with thermal energy sources. Pulsed-field ablation (PFA) offers a new method for achieving this, whilst mitigating procedural complications. Aim(s): Assess the practical feasibility and safety of additional LAPWI using PFA in conjunction with pulmonary vein isolation (PVI), as compared to PVI alone. Method(s): De-identified data from 201 patients undergoing PFA at the Victorian Heart Hospital (VHH) between October 2022 and December 2023 were analysed. Result(s): Demographics and procedurals characteristics are shown in Table 1. The addition of LAPWI prolonged the procedure by an average of 6+/-2.2 minutes and required 25+/-6.5 additional PFA applications. In the PVI + LAPWI group, one major complication occurred at day 7 with acute kidney injury. Anticoagulation was suspended, and the patient experienced a stroke with full resolution. Conversely, the PVI only group experienced three admissions for heart failure and two pericarditis cases. At 30 days, two patients (2.6%) developed atrial arrhythmias in the PVI + LAPWI group compared to seven (5.5%) in the PVI-only cohort. Conclusion(s): The addition of LAPWI by PFA is feasible and safe with minimal procedural duration extension. Longer-term follow-up is required to access efficacy and durability. [Formula presented]Copyright © 2024
Conference Name: 72nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand
Conference Start Date: 2024-08-01
Conference End Date: 2024-08-04
Conference Location: Perth Convention and Exhibition Centre, Perth, Australia
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.hlc.2024.06.648
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/52193
Type: Conference Abstract
Subjects: anticoagulation
atrial fibrillation
cerebrovascular accident
heart atrium arrhythmia
heart failure
heart left atrium
pericarditis
pulmonary vein isolation
Type of Clinical Study or Trial: Observational study (cohort, case-control, cross sectional, or survey)
Appears in Collections:Conferences

Show full item record

Page view(s)

72
checked on May 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.